NL2030433B1 - Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof - Google Patents
Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof Download PDFInfo
- Publication number
- NL2030433B1 NL2030433B1 NL2030433A NL2030433A NL2030433B1 NL 2030433 B1 NL2030433 B1 NL 2030433B1 NL 2030433 A NL2030433 A NL 2030433A NL 2030433 A NL2030433 A NL 2030433A NL 2030433 B1 NL2030433 B1 NL 2030433B1
- Authority
- NL
- Netherlands
- Prior art keywords
- malat1
- expression
- shrna
- inhibiting
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Een shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA, dat is ontworpen om zich te richten op positie 286, 743, 1048 of 4807 van de MALAT1- transcriptseguentie NR_002847.3 of een overeenkomstige positie in andere transcriptsequenties in Genbank.
2. Het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens conclusie 1, waarbij het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA is ontworpen om zich te richten op de positie 743 van de MALAT1- transcriptsequentie NR_002847.3 of een overeenkomstige site in andere transcriptsequenties in Genbank.
3. Het shRNA voor het remmen van de expressie van lang niet-coderend MALAT 1 RNA volgens conclusie 1, waarbij de sequentie van het shRNA voor het remmen van de expressie van lang niet-coderend RNA MALAT1 RNA is weergegeven als SEQ ID NOs.5 - 12.
4. HetshRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens conclusie 2 of 3, waarbij de sequentie van het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA is weergegeven als SEQ ID NOs.7 en 8.
5. Een plasmide, dat het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens willekeurig welke van conclusies 1 — 4 bevat.
6. Eenlentivirus dat shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens willekeurig welke van conclusies 1 — 4 of het plasmide volgens claim 5 bevat.
7. Toepassing van het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens willekeurig welke van conclusies 1 — 4, het plasmide volgens claim 5 of het lentivirus volgens conclusie 6 bij de behandeling van cognitieve disfunctie.
8. De toepassing volgens conclusie 7, waarbij de cognitieve disfunctie stress-geïnduceerde cognitieve disfunctie is.
9. De toepassing volgens conclusie 8, waarbij de behandeling van cognitieve disfunctie het beschermen van neuronen van de hippocampus omvat.
10. Een geneesmiddel voor de behandeling van cognitieve disfunctie, dat het shRNA voor het remmen van de expressie van lang niet-coderend MALAT1 RNA volgens willekeurig welke van conclusies 1 — 4, het plasmide volgens claim 5 of het lentivirus volgens claim 8 omvat.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111038413.5A CN113584037A (zh) | 2021-09-06 | 2021-09-06 | 抑制长链非编码RNA MALAT1表达的shRNA慢病毒及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL2030433B1 true NL2030433B1 (en) | 2023-03-21 |
Family
ID=78241247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2030433A NL2030433B1 (en) | 2021-09-06 | 2022-01-05 | Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113584037A (nl) |
NL (1) | NL2030433B1 (nl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114480309B (zh) * | 2022-02-23 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | 抑制ALKBH1表达的shRNA慢病毒及其制备和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021035128A1 (en) * | 2019-08-21 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for treating chronic myelomonocytic leukemia |
-
2021
- 2021-09-06 CN CN202111038413.5A patent/CN113584037A/zh active Pending
-
2022
- 2022-01-05 NL NL2030433A patent/NL2030433B1/en active
Non-Patent Citations (4)
Title |
---|
CAO DING-WEN ET AL: "The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 41, no. 1, 20 August 2019 (2019-08-20), pages 22 - 33, XP036976323, ISSN: 1671-4083, [retrieved on 20190820], DOI: 10.1038/S41401-019-0284-Y * |
HUI LIU ET AL: "Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, WILEY-BLACKWELL PUBLISHING ASIA, AU, vol. 44, no. 10, 24 August 2017 (2017-08-24), pages 1032 - 1041, XP071596072, ISSN: 0305-1870, DOI: 10.1111/1440-1681.12804 * |
SHANG JIN-LIN ET AL: "Cognitive improvement following ischemia/reperfusion injury induced by voluntary running-wheel exercise is associated with LncMALAT1-mediated apoptosis inhibition", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 12 February 2018 (2018-02-12), GR, XP055942126, ISSN: 1107-3756, DOI: 10.3892/ijmm.2018.3484 * |
ZHANG BIN ET AL: "Identification and Characterization of a Class of MALAT1-like Genomic Loci", CELL REPORTS, vol. 19, no. 8, 1 May 2017 (2017-05-01), US, pages 1723 - 1738, XP055941885, ISSN: 2211-1247, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505346/pdf/nihms875556.pdf> DOI: 10.1016/j.celrep.2017.05.006 * |
Also Published As
Publication number | Publication date |
---|---|
CN113584037A (zh) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105960413A (zh) | 人工dna-结合蛋白及其用途 | |
CN109641064A (zh) | 非整合病毒递送系统及其相关方法 | |
EP3935152B1 (en) | Induced photoreceptor cells and methods for their production | |
US10925976B2 (en) | Smooth muscle specific inhibition for anti-restenotic therapy | |
WO2014111876A2 (en) | Modulation of mitophagy and use thereof | |
NL2030433B1 (en) | Shrna lentivirus for inhibiting the expression of long non-coding rna malat1 and use thereof | |
Terada et al. | Sumoylation controls retinal progenitor proliferation by repressing cell cycle exit in Xenopus laevis | |
CN109576227B (zh) | 一种基于荧光素酶报告病毒的自噬细胞系构建方法 | |
Jin et al. | Effect of miR-497 on myocardial cell apoptosis in rats with myocardial ischemia/reperfusion through the MAPK/ERK signaling pathway. | |
CN110129319B (zh) | 一种PRALR的siRNA及其用途 | |
CN110066870B (zh) | hsa-miR-382-5p在制备诊断视网膜变性疾病的试剂盒中的应用 | |
CN114480309B (zh) | 抑制ALKBH1表达的shRNA慢病毒及其制备和应用 | |
CN113121667B (zh) | 一种细胞膜成孔蛋白LjGSDM及其表达与应用 | |
CN113403280B (zh) | 一种靶向kgf启动子的间充质干细胞治疗急性肺损伤筛选模型 | |
CN103667431B (zh) | 一种人ccch型锌指蛋白表达基因的用途及其相关药物 | |
CN104826130B (zh) | Msx3基因特异诱导小胶质细胞选择性极化的方法及其应用 | |
CN104368012B (zh) | 人rpl34基因的用途及其相关药物 | |
LU501763B1 (en) | SMALL INTERFERING RNAs (siRNAs) FOR INTERFERING WITH ZINC FINGER PROTEIN 24 (ZNF24) GENE EXPRESSION AND USE THEREOF IN INHIBITING CELL PROLIFERATION AND MIGRATION | |
CN111789957B (zh) | 敲低lncBCAS1-4_1细胞株与活性维生素D联用在制备抗肿瘤药物中的应用 | |
CN110129334B (zh) | IiWRKY34在调控菘蓝木脂素生物合成和抗逆胁迫反应中的应用 | |
CN114457045B (zh) | 抑制Slc2a1的RNAi腺相关病毒及其制备和应用 | |
Maritato et al. | A DNA base-specific sequence interposed between CRX and NRL contributes to RHODOPSIN expression | |
CN101502659A (zh) | Krüppel样转录因子4的新用途 | |
Pan et al. | Binding of LncRNA-DACH1 to dystrophin impairs the membrane trafficking of Nav1. 5 protein and increases ventricular arrhythmia susceptibility | |
Guadagnino | Exploring miRNAs as Modulators in Retinal Degeneration: Potential Therapeutic Tools for Inherited Retinal Dystrophies |